Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bedoradrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.70 |
| ▸ | ADRB3 | P13945 | 14/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bedoradrine SCHEMBL1261689 | 1.00 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL29385851 | 1.00 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3694819 | 1.00 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL678131 | 1.00 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL7586092 | 0.98 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3828783 | 0.98 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL29379919 | 0.98 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3828780 | 0.98 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL10026405 | 0.98 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Sulfuric Acid SCHEMBL5449137 | 0.93 | ADRB1 (0.60) | ADRB1ADRB2ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2076288-A2 | COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITOR AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER AND INCREASING NEUROGENESIS | Braincells, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008036846-A2 | COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITOR AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER AND INCREASING NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADRB1, ADRB2, ADRA2B | ADRB2 2/4885ADRB1 1/4885ADRB3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.